 |
 |
|
   |
       |
|
| ||||
 |
|
[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index] E-DRUG: Antidiarrhoeal Ercefuryl (cont'd)
E-drug: Antidiarrhoeal Ercefuryl (cont'd) --------------------------------------------- I just want to add to Jerome Sclafer's comments on nifuroxazide that Smith Kline Beecham (which markets Ambatrol (nifuroxazide) in Africa) has responded to MaLAM's criticisms about its promotional campaign in Ivory Coast. In its answer, SKB stated that "...Nifuroxazide is not appropriate for the prevention and treatment of dehydration due to diarrhoea. It is not appropriate to use nifuroxazide in infections related to potentially invasive organisms such as Shigella. In conclusion, the current campaign which still contains ambiguities on the above issues will be withdrawn immediately. All the above material will be destroyed. All future campaigns will contain no claims on Shigellas and will avoid any implication that Ambatrol has any part to play in rehydration therapy". MaLAM is pleased with this response. However, as Jerome Sclafer pointed out, the Approved Product Information is still ambiguous. Moreover, SKB did not explain how it would correct any false belief caused by its misleading promotional campaign (SKB's brochure suggested that Ambatrol was an effective treatment to prevent dehydration and to "neutralise the germs" as Shigella). MaLAM will continue the dialogue with SKB. Agnes Vitry Drug Information Pharmacist MaLAM PO Box 172 Daw Pk SA 5041 Australia phone/fax +61 8 8374 2245 [email protected] -- Send mail for the `E-Drug' conference to `[email protected]'. Mail administrative requests to `[email protected]'. For additional assistance, send mail to: `[email protected]'.
| |||
